Taysha Gene Therapies, Inc. TSHA Finance Lease Liabilities
Discontinued — last reported Q1 '26
Finance Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseLiability.
The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Taysha Gene Therapies, Inc.'s finance lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Taysha Gene Therapies, Inc.'s finance lease liabilities?
- Taysha Gene Therapies, Inc. (TSHA) reported finance lease liabilities of $275K in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s finance lease liabilities changed year-over-year?
- Taysha Gene Therapies, Inc.'s finance lease liabilities decreased by 0.0% year-over-year, from $275K to $275K.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s finance lease liabilities?
- Over 3 years (2022 to 2025), Taysha Gene Therapies, Inc.'s finance lease liabilities has grown at a -30.6% compound annual growth rate (CAGR), from $1.13M to $379K.
- What does finance lease liabilities mean?
- Present value of future payments on leases classified as finance leases under ASC 842 — treated similarly to debt on the balance sheet.